Specialization in Hematology. Campus Bio-Medico University, (Italy) Degree in Medicine and Surgery. Campus Bio-Medico University, (Italy)

Size: px
Start display at page:

Download "Specialization in Hematology. Campus Bio-Medico University, (Italy) Degree in Medicine and Surgery. Campus Bio-Medico University, (Italy)"

Transcription

1 Curriculum vitae PERSONAL INFORMATION Francesco Marchesi WORK EXPERIENCE October 2011 August 2013 Hematologist Campus Bio-Medico University, (Italy) Management of acute leukemias, high-dose chemotherapy protocols and autologous hematopoietic stem cell transplantation. Management of clinical protocols GIMEMA, IELGS, EORTC, GITMO e RTN (Rome Transplant Network). August 2013 Present Hematologist Regina Elena National Cancer Istitute, (Italy) Management of lymphoid malignancies, stem cell mobilization, high-dose chemotherapy protocols and autologous hematopoietic stem cell transplantation. Management of clinical protocols GIMEMA, IELGS, EORTC, GITMO e RTN (Rome Transplant Network). EDUCATION AND TRAINING September 2011 October 2013 Specialization in Hematology Campus Bio-Medico University, (Italy) October 2006 August 2011 Degree in Medicine and Surgery Campus Bio-Medico University, (Italy) ADDITIONAL INFORMATION Expertise My main fields of clinical interest are diagnosis and treatment of lymphoid malignancies, stem cell mobilization, high-dose chemotherapy protocols and autologous hematopoietic stem cell transplantation. My main filed of clinical research are the management of viral and bacterial infectious complication in hematologic patients and biology of aggressive non-hodgkin lymphomas. Publications Publications "in exteso" Focus on fotemustine. De Rossi A, Rossi L, Laudisi A, Sini V, Toppo L, Marchesi F, Tortorelli G, Leti M, Turriziani M, Aquino A, Bonmassar E, De Vecchis L, Torino F. J Exp Clin Cancer Res 25, 4, Novel role of triazenes in haematological malignancies: pilot study of temozolomide, lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia. Caporaso P, Turriziani M, Venditti A, Marchesi F, Buccisano F, Tirindelli MC, Alvino E, Garbin A, Tortorelli G, Toppo L, Bonmassar E, D Atri S, Amadori S. DNA Repair 2007; 6: Triazene compounds: mechanism of action and related DNA repair systems. Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, De Vecchis L. Pharmacol Res 2007; 56: Fibrin glue for endoscopic gastrointestinal bleeding in patients with impaired haemostasis. Tirindelli MC, Greco R, Marchesi F, Gabbrielli A, Avvisati G. Transfusion Med 2008; 18: Skin lesion associated to cerebral involvement in multiple myeloma. Annibali O, Marchesi F, Romeo AA, Bianchi A, Tirindelli MC, Avvisati G. Slide of the month, BloodMed 2008 Aug. Zigomicosi dei seni paranasali in paziente affetto da linfoma non-hodgkin resistente. 6/7/15 European Union, Page 1 / 6

2 Annibali O, Marchesi F, Avvisati G. OnMedicine Case Studies 2009, marzo pagg A case of primary MALT lymphoma of the endometrium presenting as an asymptomatic polyp. Annibali O, Romeo AA, Agostinelli C, Marchesi F, Natale A, De Muro M, Tirindelli MC, Pileri SA, Avvisati G. Ann Hematol 2009; 88: Relapse of IgA multiple myeloma presenting as obstructive jaundice and abdominal pain. Annibali O, Marchesi F, Petrucci MT, Tirindelli MC, Avvisati G. Onkologie 2009; 32: Hematologic issues in cervical spine surgery. Avvisati G, Annibali O, Cerchiara E, De Muro M, Greco R, Marchesi F, Nobile C, Olimpieri O, Romeo A, Tirindelli MC. In Denaro L, D Avella D, Denaro V. Pitfalls in Cervical Spine Surgery, Springer-Verlag Berlin Heidelberg 2010; chapter 2, pagg Cytogenetic abnormalities in adult non-promyelocytic acute myeloid leukemia: a concise review. Marchesi F, Annibali O, Cerchiara E, Tirindelli MC, Avvisati G. Crit Rev Oncol Hematol 2011; 80: Systemic strongyloidiasis and primary aspergillosis of digestive tract in a patient with T-cell acute lymphoblastic leukemia. Marchesi F, Lepanto D, Annibali O, Cerchiara E, Tirindelli MC, Bianchi A, Sedati P, Onetti Muda A, Avvisati G. Leuk Res 2011; 35: Pathogenetic, clinical and prognostic features of adult t(4;11)(q21;q23)/mll-af4 positive B-cell acute lymphoblastic leukemia. Marchesi F, Girardi K, Avvisati G. Adv Hematol 2011; 2011: The potential role of pre-transplant HBcIgG seropositivity as predictor of clinically relevant Cytomegalovirus infection in patients with lymphoma undergoing autologous hematopoietic stem cell transplantation: a study from the Rome Transplant Network. Marchesi F, Giannotti F, Avvisati G, Petti MC, Pimpinelli F, Paba P, Dessanti ML, Cerretti R, Tirindelli MC, Picardi A, D Andrea M, Spadea A, Ensoli F, Perno CF, Mengarelli A, Arcese W. Am J Hematol 2012; 87: Tuberculosis meningoencephalitis in a patient with hairy cell leukemia in complete remission. Girardi K, Paviglianiti A, Cirillo M, Bianchi A, Gherardi G, Annibali O, Cerchiara E, Marchesi F, Tomarchio V, Miglio C, Tirindelli M, Onetti Muda A, Avvisati G. J Clin Exp Hemopat 2012; 52: Triazene compounds in the treatment of acute myeloid leukemia: a short review and a case report. Bonmassar L, Marchesi F, Pascale E, Franzese O, Margison GP, Bianchi A, D'Atri S, Bernardini S, Lattuada B, Bonmassar E, D'Aquino A. Curr Med Chemistry 2013; 20: A retrospective study on 73 elderly patients ( 75 years) with aggressive B-cell Non Hodgkin lymphoma: clinical significance of treatment intensity and comprehensive geriatric assessment. Marchesi F, Cenfra N, Altomare L, Dessanti ML, Mecarocci S, Cerchiara E, Rago A, D'Andrea M, Tomarchio V, Olimpieri OM, Tirindelli MC, Mengarelli A, Petti MC, Avvisati G, Cimino G. J Geriatr Oncol 2013; 4: High incidence of post-transplant Cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with Bortezomib-based regimens: a survey from the Rome Transplant Network. Marchesi F, Mengarelli A, Giannotti F, Tendas A, Anaclerico B, Porrini R, Picardi A, Cerchiara E, Dentamaro T, Chierichini A, Romeo A, Cudillo L, Montefusco E, Tirindelli MC, De Fabritiis P, Annino L, Petti MC, Monarca B, Arcese W, Avvisati G. Transpl Infect Dis 2014; 16: High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to a poor clinical outcomes in patients with diffuse large-b cell lymphoma. Marchesi F, Cirillo M, Bianchi A, Gately M, Olimpieri OM, Cerchiara E, Renzi D, Micera A, Balzamino BO, Bonini S, Onetti Muda A, Avvisati G. Hematol Oncol 2014 (in press). A case of transplantation-associated thrombotic microangiopathy with cardiac involvement successfully treated with plasma exchange. Paviglianiti A, Tomarchio V, Spurio S, Cerchiara E, Marchesi F, Tirindelli MC, Avvisati G. Indian J Hematol Blood Transfus 2014; 30(s1): /7/15 European Union, Page 2 / 6

3 Evaluation of risk of symptomatic Cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single institution study. Marchesi F, Pimpinelli F, Dessanti ML, Gumenyuk S, Palombi F, Pisani F, Romano A, Spadea A, Maschio M, Ensoli F, Mengarelli A. Transpl Infect Dis 2014; 16: Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy. Girmenia C, Rossolini GM, Piciocchi A, Bertaina A, Pisapia G, Pastore D, Sica S, Severino A, Cudillo L, Ciceri F, Scimè R, Lombardini L, Viscoli C, Rambaldi A (collaborator) Bone Marrow Transplant 2014 (in press). Comparison between biosimilar filgrastim vs other G-CSF formulations (originator filgrastim, pegfilgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network Marchesi F, Cerchiara E, Dessanti ML, Gumenyuk S, Franceschini L, Palombi F, Pisani F, Romano A, Spadea A, Pupo L, Annibali O, La Malfa A, Arcese W, Mengarelli A. Br J Haematol 2015; 169: Flow cytometry characterization in central nervous system and pleural effusion multiple myeloma infiltration: an italian national cancer institute experience. Marchesi F, Masi S, Summa V, Gumenyuk S, Merola R, Orlandi G, Cigliana G, Palombi F, Pisani F, Romano A, Spadea A, Papa E, Canfora M, De Bellis F, Conti L, Mengarelli A, Cordone I. Br J Haematol 2015 (in press). Biosimilar filgrastim (Zarzio ) vs Lenograstim (Myelostim ) for peripheral blood stem cell mobilization in adult patients with lymphoma and myeloma: a single center experience. Marchesi F, Vacca M, Gumenyuk S, Pandolfi A, Renzi D, Palombi F, Pisani F, Romano A, Spadea A, Ipsevich F, Santinelli S, De Rienzo M, Papa E, Canforma M, Laurenzi L, Foddai ML, Pierelli L, Mengarelli A. Leuk Lymphoma 2015 (in press). Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by 90Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma. Pisani F, Sciuto R, Dessanti ML, Giannarelli D, Kayal R, Rea S, Marchesi F, Marino M. Exp Hematol Oncol 2015 (in press). Congress abstracts Methylating triazene compounds and MGMT inhibitors: preclinical and clinical studies in haematological malignancies. D Atri S, Caporaso P, Turriziani M, Marchesi F, Buccisano F, Venditti A, Tirindelli MC, Amadori S, Alvino E, Mazzone C, Garbin A, Bonmassar E. Oral presentation, 2nd International Conference MGMT and Alkylating Drug Resistance Favorite Park Hotel, June , Mainz, Germania. Triazene compounds and MGMT inhibitors in acute leukemia: preclinical and clinical studies. Marchesi F, Turriziani M, Venditti A, Caporaso P, Tortorelli G, Buccisano F, D Atri S, Tirindelli MC, Amadori S, Bonmassar E. (Poster presentation, 41th Congress of the Italian Society of Hematology, Bologna, October ). Haematologica 2007; 92 (s3): CHOD regimen in extramedullary multiple myeloma presenting as relapse after PBSCT (Peripheral Blood Stem Cell Transplantation) or salvage therapies. Annibali O, Marchesi F, Cerchiara E, De Muro M, Olimpieri O, Nobile C, Tirindelli MC, Petrucci MT, Avvisati G. (Abstract, 42th Congress of the Italian Society of Hematology, Milano, 2009). Haematologica 2009; 94 (s4): Fibrin glue directly applied on damaged mucosa during cystoscopy is highly effective to treat severe, refractory, haemorragic cystitis after allogenic transplant. Tirindelli MC, Flammia G, Cudillo L, Dentamaro T, Picardi A, Annibali O, Tendas A, Cupelli L, Nobile C, Marchesi F, Cerretti R, Mirabile M, De Angelis G, Girardi K, De Fabritiis P, Avvisati G, Arcese W. Oral presentation, 36th Annual Meeting of the European Group for Blood and Marrow Transplantation, Vienna, marzo Analisi retrospettiva di 20 pazienti con linfoma non-hodgkin diffuse a grandi cellule B ad alto rischio sottoposti ad intensificazione con trapianto autologo di cellule staminali ematopoietiche in prima linea di trattamento. 6/7/15 European Union, Page 3 / 6

4 Marchesi F, Girardi K, Tomarchio V, Giannotti F, Annibali O, Cerchiara E, Mengarelli A, Petti MC, Tirindelli MC, Arcese W, Avvisati G. Presentazione orale, La malattia minima residua in oncoematologia: metodi e significato clinico nell era delle terapie mirate, Sala conferenze, Università degli studi di Roma La Sapienza Polo di Latina, 7 febbraio Diagnostic strategies and risk factors for cytomegalovirus infection in patients with lymphoma undergoing autologous transplantation: a retrospective analysis from the Rome Transplant Network. Marchesi F, Giannotti F, Petti MC, Avvisati G, Pimpinelli F, Paba P, Dessanti ML, Cerretti R, Tirindelli MC, Picardi A, D Andrea M, Spadea A, Ensoli F, Perno CF, Mengarelli A, Arcese W. (Poster presentation, 16th Congress of the European Hematology Association, London 11 June 2011). Haematologica 2011; 96 (s2): 412. Retrospective analysis of 20 patients with high risk diffuse large B-cell lymphoma undergoing front-line intensification with autologous hematopoietic stem cell transplantation: a Rome Transplant Network study. Marchesi F, Giannotti F, Mengarelli A, Annibali O, Cudillo L, Dessanti ML, Cerchiara E, Vaccarini S, D Andrea M, Spadea A, Cantonetti M, Petti MC, Arcese W. (Abstract, 43th Congress of the Italian Society of Hematology, Napoli, 2011). Haematologica 2011; 96 (s3): 192. Retrospective analysis of 41 non-hodgkin lymphoma (NHL) patients aged 75 years undergoing chemo-immunotherapy. Marchesi F, Cenfra N, Tomarchio V, Rago A, Annibali O, Cerchiara E, Girardi K, Mecarocci S, Olimpieri OM, Altomare L, Tirindelli MC, Avvisati G, Cimino G. (Abstract, 43th Congress of the Italian Society of Hematology, Napoli, 2011). Haematologica 2011; 96 (s3): Bortezomib-based therapy increases the incidence of post-transplant viral infections in multiple myeloma patients undergoing ASCT: retrospective analysis from the Rome Transplant Network. Marchesi F, Mengarelli A, Angelini S, Giannotti F, Porrini R, Picardi A, Chierichini A, Cerchiara E, Dentamaro T, Cudillo L, Anaclerico B, Tendas A, Montefusco E, Romano A, Tirindelli MC, De Fabritiis P, Annino L, Petti MC, Monarca B, Avvisati G, Arcese W. (Poster presentation, 17th Congress of the European Hematology Association, Amsterdam 16 June 2012). Haematologica 2012; 97(s1): Influence of Plerixafor on viability of peripheral blood stem cells collected by apheresis. Postorino M, Lanti A, Zizzari A, Franceschini L, Pupo L, Del Proposto G, Provenzano I, Basso L, Bonchi C, De Masi A, Docino F, Agostini F, Massanelli R, Marchesi F, Renzi D, Adorno G, Cantonetti M. (Abstract, 39th Annual Meeting of the European Group for Blood and Marrow Transplantation, London 2013). Bone Marrow Transplant 2013; 48 (suppl. 2s): S1-S574. The efficacy of CHOEP chemotherapy regimen administered in association with monoclonal antibody anti-cd52 Alemtuzumab in cutaneous T-cell lymphoma (CTCL) and systemic T-cell lymphoma with cutaneous involvement (PTCL). Postorino M, De Santis G, Marchesi F, Provenzano I, Franceschini L, Pupo L, Rizzo M, Giannì L, Gumenyuk S, Tonialini L, Fiorelli E, Renzi D, Zizzari A. (Abstract, 12th International Congress of Malignant Lymphoma, Lugano 2013). Hematol Oncol 2013; 31 (Suppl. 1): The policy of Rome Transplant Network (RTN) for allogeneic hematopoietic stem celle transplantation (HSCT) in patients with high risk haematological malignancies. Picardi A, Mangione I, Di Piazza F, Cudillo L, Cerretti R, De Angelis G, Dentamaro T, Tirindelli MC, Mengarelli A, Ferrari A, Chierichini A, Marchesi F, Andreani M, Testi M, Arcese W. (Abstract, 44th Congress of the Italian Society of Hematology, Verona, 2013). Haematologica 2013; 98(s3): 19. Extramedullary relapse of acute promyelocitic leukemia with ear, cutis and central nervous system involvement successfully treated with ATO, ATRA and intrathecal chemotherapy. Tomarchio V, Marchesi F, Berti P, Cerchiara E, Renzi D, Bianchi A, Avvisati G. Poster presentation, 6th Internationa Symposium on Acute Promyelocytic Leukemia, Rome, 29 September - 2 October High density of CD68+/CD163+ Tumor-Associated Macrophages (M2-TAM) at diagnosis is a poor prognostic factor in Diffuse Large-B Cell Lymphoma (DLBCL). Marchesi F, Cirillo M, Bianchi A, Gately M, Olimpieri OM, Cerchiara E, Micera A, Balzamino BO, Bonini S, Onetti Muda A, Avvisati G. (Poster presentation, 43th Congress of the Italian Society of Hematology, Verona, 2013). Haematologica 2013; 98(s3): 77. Strategy, policy and algorithm of adult patients with high risk haematological malignancies candidated to an allogeneic hematopoietic stem cell transplant: an analysis from the Rome Transplant Network. 6/7/15 European Union, Page 4 / 6

5 Picardi A, Cudilli L, Cerretti R, De Angelis G, De Fabritiis P, Dentamaro T, Avvisati G, Tirindelli MC, Mengarelli A, Marchesi F, Montefusco E, Ferrari A, Chierichini A, Anaclerico B, Andreani M, Testi M, Mangione I, Di Piazza F, Arcese W. (Abstract, 40th Annual Meeting of the European Society for Blood and Marrow Transplantation, Milano 2014). Bone Marrow Transplant 2014; 49: s210. Biosimilar G-CSF (Zarzio ) is able to determine a regular neutrophilis engraftment after autologous stem cell transplantation: a single institution experience. Marchesi F, Gumenyuk S, Dessanti ML, Palombi F, Pisani F, Romano A, Spadea A, Mengarelli A. (Abstract, 40th Annual Meeting of the European Society for Blood and Marrow Transplantation, Milano 2014). Bone Marrow Transplant 2014; 49: s520. Lenograstim (Myelostim ) vs biosimilar Filgrastim (Zarzio ) for autologous peripheral blood stem cells mobilization in adult patients with hematologic malignancies: a single institution experience. Marchesi F, Gumenyuk S, Vacca M, Pandolfi N, Dessanti ML, Palombi F, Pisani F, Romano A, Spadea A, Mengarelli A. (Poster presentation, 40th Annual Meeting of the European Society for Blood and Marrow Transplantation, Milano 31 March 2014). Bone Marrow Transplant 2014; 49: s214. Tandem autologous stem cell transplantation doesn't increase the risk of symptomatic Cytomegalovirus reactivation in myeloma patients in the era of the novel agents: a single Institution study. Marchesi F, Pimpinelli F, Dessanti ML, Gumenyuk S, Palombi F, Pisani F, Romano A, Spadea A, Maschio M, Ensoli F, Mengarelli A. (Poster presentation, 19th Congress of the European Hematology Association, Milano 13 June 2014). Haematologica 2014; 99(s1): 193. FCR (Fludarabine, Cyclophosphamide, Rituximab) followed by 90yttrium Ibritumomab Tiuxetan for the treatment of relapsed grades 1 and 2 follicular lymphoma. Long term efficacy and safety results of 9 cases. Pisani F, Dessanti ML, Giannarelli D, Kayal R, Marchesi F, Sciuto R, Rea S, Maini CL, Marino M. (Abstract, 56th American Society of Hematology Annual Meeting, San Francisco, CA, 2014). Blood 2014; 124: Survival of patients with high-risk hematological malignancy after allogeneic transplant from HLA identical sibling is comparable to that patients transplanted from haploidentical, unmanipulated bone marrow donor: results of a matched-pair analysis from the Rome Transplant Network. Arcese W, Cerretti R, Cudillo L, De Angelis G, Picardi A, De Fabritiis P, Dentamaro T, Tendas A, Cupelli L, Mengarelli A, Marchesi F, Chierichini A, Anaclerico B, Tirindelli MC, Cerchiara E, Montefusco E, Ferrari A, Mariotti B, Ceresoli E, Adorno G, Di Piazza F, Gentile G, Sarmati L. (Abstract) Poster presentation, P1223, 56th American Society of Hematology Annual Meeting and Exposition, San Francisco, CA, USA, 6 december Allogeneic transplant in acute myeloid leukemia (AML): according to the local policy of the Rome Transplant Network (RTN): a intention-to-treat analysis. Arcese W, Amadori S, Cerretti R, Cudillo L, De Angelis G, Venditti A, Buccisano F, Cantonetti M, Mangione I, Andreani M, Testi M, Rapanotti MC, De Fabritiis P, Dentamaro T, Cupelli L, Tendas A, Tirindelli MC, Annibali O, Saltarelli F, Mengarelli A, Marchesi F, Gumenyuk S, Chierichini A, Anaclerico B, Tafuri A, Montefusco E, Ferrari A, Naso V, Di Piazza F, Pisardi A. (Abstract) Oral presentation, O099, 41th Annual Meeting of the European Society for Blood and Marrow Transplantation, Istanbul, 24 March 2015). The impact of HLA matching on the clinical outcome of hematopoietic stem cell transplantation from volunteer unrelated donors according to the uniform, prospective program of the Rome Transplant Network. Picardi A, Cudillo L, Mangione I, De Angelis G, Mariotii B, Di Piazza F, Cantonetti M, Ceresoli E, Rapanotti C, De Fabritiis P, Dentamaro T, Tirindelli MC, Annibali A, Mengarelli A, Marchesi F, Chierichini A, Anaclerico B, Montefusco E, Ferrari A, Andreani M, Testi M, Cerretti R, Arcese W. (Abstract) Poster presentation, P065, 41th Annual Meeting of the European Society for Blood and Marrow Transplantation, Istanbul, 23 March 2015). Chemotherapy-induced nausea and vomiting in adult patients after hematopoietic stem cell transplantation: a survey from the Quality Of Life Working Party of the Rome Transplant Network (RTN). Tendas A, Annibali O, Sollazzo F, D'Apolito A, Cacciaraichi S, Viggiani C, Conte E, Molinari V, Di Veroli A, Chierichini A, Mauroni MR, Papa C, Saltarelli D, Carli I, Marchesi F, Dentamaro T, De Fabritiis P, Arcese W. (Abstract) Poster presentation, P177, 41th Annual Meeting of the European Society for Blood and 6/7/15 European Union, Page 5 / 6

6 Marrow Transplantation, Istanbul, 23 March 2015). A refined composite clinical score for the early identification of the predicted Poor Mobilizers (PM): a GITMO analysis. Attolico I, Olivieri J, Nuccorini R, Pascale P, Chiarucci M, Poiani M, Gozzer M, Capria S, Mele G, Melpignano A, Perseghin P, Pioltelli P, Martino M, Moscato T, Musto P, Pietrantuono G, Corradini O, Farina L, Nassi L, Margiotta Casaluci G, Di Marco A, Spadaro A, Gumenyuk S, Marchesi F, Lanza F, Brambilla P, Pini M, Zallio F, Marktel S, Gattilo S, Sica S, Ausoni G, Merli F, Codeluppi K, Specchia G, Pastore D, Pizzuti M, Di nardo E, Olivieri A. (Abstract) Poster presentation, P411, 41th Annual Meeting of the European Society for Blood and Marrow Transplantation, Istanbul, 24 March 2015). Unique chemotherapy based reduced intensity conditioning regimen for patients transplanted from HLA identical siblings, haploidentical or volunteer unrelated donors: a prospective study from the Rome Transplant Network. Cerretti R, Picardi A, Cudillo L, De Angelis G, Mariotti B, Mengarelli A, Marchesi F, Mangione I, Testi M, De Fabritiis P, Dentamaro T, Tirindelli MC, Saltarelli F, Chierichini A, Anaclerico B, Tafuri A, Ferrari A, Di Piazza F, Arcese W. (Abstract) Poster presentation, P650, 41th Annual Meeting of the European Society for Blood and Marrow Transplantation, Istanbul, 24 March 2015). Minimal residual disease by multiparameter flow cytometry in myeloma patients undergoing an upfront tandem ASCT: a real life single-institution study. Cordone I, Marchesi F, Masi S, Summa V, Dessanti ML, Gumenyuk S, Merola R, Cigliana G, Orlandi G, Palombi F, Pisani F, Romano A, Spadea A, Conti L, Petti MC, Mengarelli A. (Abstract) Poster presentation, P352, 41th Annual Meeting of the European Society for Blood and Marrow Transplantation, Istanbul, 23 March 2015). Projects Memberships Membro della Società Italiana di Ematologia dal 2007 Membro del Clinical Board del Rome Transplant Network dal 2013 Other Relevant Information 6/7/15 European Union, Page 6 / 6

PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA

PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA 2012 1 31,, PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA Version 1.0 2012 DIVISION OF HAEMATOLOGY / ONCOLOGY DEPARTMENT OF MEDICINE KAOHSING VETERAN GENERAL HOSPTIAL General Guide Diagnosis 1.Adequate

More information

MEDICAL COVERAGE POLICY

MEDICAL COVERAGE POLICY Important note Even though this policy may indicate that a particular service or supply is considered covered, this conclusion is not necessarily based upon the terms of your particular benefit plan. Each

More information

Outline of thesis and future perspectives.

Outline of thesis and future perspectives. Outline of thesis and future perspectives. This thesis is divided into two different sections. The B- section involves reviews and studies on B- cell non- Hodgkin lymphoma [NHL] and radioimmunotherapy

More information

STUDY PROTOCOL. Fabio Ciceri M.D. Istituto Scientifico H. San Raffaele Dept. of of Oncology, Haematology/Transplant Unit I-20132 Milan

STUDY PROTOCOL. Fabio Ciceri M.D. Istituto Scientifico H. San Raffaele Dept. of of Oncology, Haematology/Transplant Unit I-20132 Milan STUDY PROTOCOL Clinical phase II trial to evaluate the safety and efficacy of treosulfan combined with cytarabine and fludarabine prior to autologous haematopoietic stem cell transplantation in elderly

More information

Stem Cell Transplantation

Stem Cell Transplantation Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance

More information

Relapsed or Refractory Adult Acute Lymphoblastic Leukemia (ALL): Distinct Patient Populations With Significant Unmet Medical Need

Relapsed or Refractory Adult Acute Lymphoblastic Leukemia (ALL): Distinct Patient Populations With Significant Unmet Medical Need Relapsed or Refractory Adult Acute Lymphoblastic Leukemia (ALL): Distinct Patient Populations With Significant Unmet Medical Need Hagop M. Kantarjian, MD Chairman, Leukemia Department Department of Hematology

More information

Hematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine

Hematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells

More information

DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT

DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT www.narayanahealth.org DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT About Narayana Health City Narayana Health, one of India's largest and the world's most economical healthcare service providers

More information

DECISION AND SUMMARY OF RATIONALE

DECISION AND SUMMARY OF RATIONALE DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in

More information

Collaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma (CALM) Additional Questionnaire (MED C) INCLUSION CRITERIA CALM STUDY

Collaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma (CALM) Additional Questionnaire (MED C) INCLUSION CRITERIA CALM STUDY Additional Questionnaire (MED C) CALM study Inclusion period: 01/01/2008 to 31/12/2011 PATIENT REGISTRATION FORM Disease Diagnosis Lymphoma S Non Hodgkin Lymphoma (NHL) Mature B-cell neoplasm Follicular

More information

Bendamustine for the fourth-line treatment of multiple myeloma

Bendamustine for the fourth-line treatment of multiple myeloma LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for the fourth-line treatment of multiple myeloma Contents Summary 1 Background 2 Epidemiology 3 Cost 6 References 7 Summary There is no standard

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll

More information

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype? Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in

More information

STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA

STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA Sundar Jagannath MD Professor of Medicine St. Vincent s Comprehensive Cancer Center New York, NY Where is transplant today in the management of Myeloma? Autologous

More information

Aggressive lymphomas. Michael Crump Princess Margaret Hospital

Aggressive lymphomas. Michael Crump Princess Margaret Hospital Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:

More information

Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points

Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Bone Marrow Transplantation

More information

Mantle Cell Lymphoma Understanding Your Treatment Options

Mantle Cell Lymphoma Understanding Your Treatment Options New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department

More information

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons LYMPHOMA BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons Normal development of lymphocytes Lymphocyte proliferation and differentiation:

More information

Stem Cell Transplantation In Patients with Fanconi Anemia

Stem Cell Transplantation In Patients with Fanconi Anemia Stem Cell Transplantation In Patients with Fanconi Anemia FARF Annual Family Meeting 6/28/15 Casco, ME Parinda A. Mehta, M.D. Cincinnati Children s Hospital Medical Center Improvements in Unrelated Donor

More information

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014 ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the

More information

The evolving role of stem cell transplantation in acute promyelocytic leukemia

The evolving role of stem cell transplantation in acute promyelocytic leukemia The evolving role of stem cell transplantation in acute promyelocytic leukemia 1 S.M. Ramadan, 2 L. Cicconi, 1, 3 F. Lo-Coco I Simposio Conjunto EHA - SAH 1Department of Biomedicine and Prevention, University

More information

Long Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia

Long Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia Long Term Low Dose Chemotherapy in the Treatment of Acute Myeloid Leukemia Murat TOMBULO LU*, Seçkin ÇA IRGAN* * Department of Hematology, Faculty of Medicine, Ege University, zmir, TURKEY ABSTRACT In

More information

Pro Cure in Multiple Myeloma. Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany

Pro Cure in Multiple Myeloma. Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany Pro Cure in Multiple Myeloma Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany Pro Cure in Multiple Myeloma Several hematological malignancies can be cured

More information

Interesting Case Series. Periorbital Richter Syndrome

Interesting Case Series. Periorbital Richter Syndrome Interesting Case Series Periorbital Richter Syndrome MarkGorman,MRCS,MSc, a Julia Ruston, MRCS, b and Sarath Vennam, BMBS a a Division of Plastic Surgery, Royal Devon and Exeter Hospital, Exeter, Devon,

More information

Stem Cell Transplantation for Acute Lymphoblastic Leukemia

Stem Cell Transplantation for Acute Lymphoblastic Leukemia Stem Cell Transplantation for Acute Lymphoblastic Leukemia Mona Shafey MD, FRCPC Bone Marrow Transplant Fellow Alberta Blood and Marrow Transplant Program 1 of 14 Stem Cell Transplantation for Acute Lymphoblastic

More information

ACUTE MYELOID LEUKEMIA (AML),

ACUTE MYELOID LEUKEMIA (AML), 1 ACUTE MYELOID LEUKEMIA (AML), ALSO KNOWN AS ACUTE MYELOGENOUS LEUKEMIA WHAT IS CANCER? The body is made up of hundreds of millions of living cells. Normal body cells grow, divide, and die in an orderly

More information

Lymphomas after organ transplantation

Lymphomas after organ transplantation Produced 21.03.2011 Revision due 21.03.2011 Lymphomas after organ transplantation People who have undergone an organ transplant are more at risk of developing lymphoma known as post-transplant lymphoproliferative

More information

Blood-Forming Stem Cell Transplants

Blood-Forming Stem Cell Transplants Blood-Forming Stem Cell Transplants What are bone marrow and hematopoietic stem cells? Bone marrow is the soft, sponge-like material found inside bones. It contains immature cells known as hematopoietic

More information

Treating Minimal Residual Disease in Acute Leukemias: How low should you go?

Treating Minimal Residual Disease in Acute Leukemias: How low should you go? Treating Minimal Residual Disease in Acute Leukemias: How low should you go? Ramsie Lujan, Pharm.D. PGY1 Pharmacy Practice Resident Methodist Hospital, San Antonio, Texas Pharmacotherapy Education and

More information

National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div.

National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div. Dated 21 st November 2014 NPPA Invites Comments of Pharmaceutical Industry & Trade, Consumer Organisations, Public Health Experts and other Stakeholders on the Recommendations of Tata Memorial Centre under

More information

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including

More information

Daiichi Sankyo to Acquire Ambit Biosciences

Daiichi Sankyo to Acquire Ambit Biosciences For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please

More information

cancer cancer Hessamfar-Bonarek M et al. Int. J. Epidemiol. 2010;39:135-146

cancer cancer Hessamfar-Bonarek M et al. Int. J. Epidemiol. 2010;39:135-146 Hematopoietic Stem Cell Transplant in HIV- related lymphoma Song Zhao, MD PhD Hematology-Oncology Program University of Washington/FHCRC Underlying Causes of Death in HIV-infected Adults 2000 2005 cancer

More information

Lymphoma Diagnosis and Classification

Lymphoma Diagnosis and Classification Lymphoma Diagnosis and Classification By Atef Shrit, MD, Pathology B- and T/NK-cell lymphomas are clonal neoplasms of immature and mature B-lymphocytes, T-lymphocytes or natural killer cells at various

More information

GRANIX (tbo-filgrastim)

GRANIX (tbo-filgrastim) RATIONALE FOR INCLUSION IN PA PROGRAM Background Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils. A person with severe neutropenia has an absolute neutrophil

More information

FastTest. You ve read the book... ... now test yourself

FastTest. You ve read the book... ... now test yourself FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections

More information

亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引

亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引 前 言 : 惡 性 淋 巴 瘤 ( 或 簡 稱 淋 巴 癌 ) 乃 由 體 內 淋 巴 系 統 包 括 淋 巴 細 胞 淋 巴 管 淋 巴 腺 及 一 些 淋 巴 器 官 或 組 織 如 脾 臟 胸 腺 及 扁 桃 腺 等 所 長 出 的 惡 性 腫 瘤 依 腫 瘤 病 理 組 織 型 態 的 不 同 可 分 為 何 杰 金 氏 淋 巴 瘤 (Hodgkin s disease) 與 非 何 杰 金

More information

What is non-hodgkin lymphoma, how is it treated, and what is the unmet need?

What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? What is non-hodgkin lymphoma, how is it treated, and what is the unmet need? Tim Illidge BSc PhD MRCP FRCR FRCPath Institute of Cancer Sciences, University of Manchester Manchester Cancer Research Centre,

More information

2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders

2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders UPDATE ECIL-4 2011 2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders Jan Styczynski, Hermann Einsele, Rafael de la Camara, Catherine Cordonnier,

More information

Guidelines for the Management of Chronic Lymphocytic Leukaemia (CLL)

Guidelines for the Management of Chronic Lymphocytic Leukaemia (CLL) Guidelines for the Management of Chronic Lymphocytic Leukaemia (CLL) Version History Version Date Summary of Change/Process 2.0 08.05.08 Endorsed by the Governance Committee 2.1 16.02.11 Circulated at

More information

Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma

Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma a report by Martin Dreyling Therapeutic Options in Refractory or Relapsed CD20-positive Follicular Lymphoma Head, Lymphoma Section, Department of Medicine III, University Hospital Großhadern, Ludwig Maximilians-University

More information

Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics

Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics Are CAR T-Cells the Solution for Chemotherapy Refractory Diffuse Large B-Cell Lymphoma? Umar Farooq, MD University of Iowa Hospitals and Clinics Disclosure(s) I do not intend to discuss an off-label use

More information

Acute Lymphoblastic Leukemia (Adult) Including Lymphoblastic lymphoma

Acute Lymphoblastic Leukemia (Adult) Including Lymphoblastic lymphoma Acute Lymphoblastic Leukemia (Adult) Including Lymphoblastic lymphoma Updated April 2008 by Dr. Richard Wells* Updates: Minor changes only Introduction Acute lymphocytic leukemia (ALL) is a relatively

More information

What is a Stem Cell Transplantation?

What is a Stem Cell Transplantation? What is a Stem Cell Transplantation? Guest Expert: Stuart, MD Associate Professor, Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Drs. Ed and Ken. I am

More information

Guidelines for the Management of Follicular Lymphoma

Guidelines for the Management of Follicular Lymphoma Guidelines for the Management of Follicular Lymphoma Scope The following guidance for first- and second-line therapy applies to follicular lymphoma histological grades 1, 2 and 3a according to the World

More information

Non-Hodgkin s Lymphoma

Non-Hodgkin s Lymphoma Non-Hodgkin s Lymphoma Luis Fayad, MD Assistant Professor Clinical Medical Director Lymphoma/Myeloma Department Non-Hodgkin s Lymphoma Non-Hodgkin s lymphomas (NHL) are a heterogeneous group of malignant

More information

Hematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia

Hematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia Hematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia Policy Number: Original Effective Date: MM.07.026 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 04/26/2013 Section:

More information

Anti-HCV therapy in HCV-related NHL

Anti-HCV therapy in HCV-related NHL Gabriele Pozzato M.D. University of Trieste Anti-HCV therapy in HCV-related NHL Questions about HCV+ in NHL Is the NHL related with HCV infection? Which is the best therapeutic strategy? Is the antiviral

More information

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004,

More information

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy

More information

Why discuss CLL? Common: 40% of US leukaemia. approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time

Why discuss CLL? Common: 40% of US leukaemia. approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time Why discuss CLL? Common: 40% of US leukaemia approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time Median age of dx is 65 (30s. Incurable, survival 2-202 20 years Require ongoing supportive care

More information

LEUCEMIA MIELOIDE ACUTA. A.M. Carella U.O.C. Ematologia IRCCS AOU San Martino IST, Genova

LEUCEMIA MIELOIDE ACUTA. A.M. Carella U.O.C. Ematologia IRCCS AOU San Martino IST, Genova LEUCEMIA MIELOIDE ACUTA A.M. Carella U.O.C. Ematologia IRCCS AOU San Martino IST, Genova Impact of mutational analysis in AML C. Thiede Optimal acute myeloid leukemia therapy in 2012 H. Dombret Acquired

More information

Tumori emopoietici in gravidanza. Alessandro Rambaldi Ematologia Azienda Ospedaliera Papa Giovanni XXIII Bergamo

Tumori emopoietici in gravidanza. Alessandro Rambaldi Ematologia Azienda Ospedaliera Papa Giovanni XXIII Bergamo Tumori emopoietici in gravidanza Alessandro Rambaldi Ematologia Azienda Ospedaliera Papa Giovanni XXIII Bergamo Caravaggio, 17-5-2013 Hematologic malignancies in pregnancy INCIDENCE The incidence of hematologic

More information

Asymptomatic or smoldering myeloma with no symptoms and slow growing cancer cells

Asymptomatic or smoldering myeloma with no symptoms and slow growing cancer cells ESSENTIALS Multiple Myeloma Diagnosed with Multiple Myeloma? It s important to understand everything you can about your diagnosis, possible treatments, and places to go for support and care. Cancer is

More information

information for payers and referrers

information for payers and referrers a d u lt s t e m c e l l t r a n s p l a n tat i o n p r o g r a m information for payers and referrers Spring 2014 For more information, visit www.dfbwcc.org/bmt. o u r expertise Since its founding in

More information

The use of monoclonal antibodies in the setting of HSCT

The use of monoclonal antibodies in the setting of HSCT The use of monoclonal antibodies in the setting of HSCT S Montoto, Barts Cancer Institute, London, UK Geneva 3/April/2012 www.ebmt.org Some definitions of interest: Ab and Ag Antibody (Ab)=Immunoglobulin

More information

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade

More information

Malignant Lymphomas and Plasma Cell Myeloma

Malignant Lymphomas and Plasma Cell Myeloma Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations

More information

Treatment of low-grade non-hodgkin lymphoma

Treatment of low-grade non-hodgkin lymphoma Produced 28.02.2011 Due for revision 28.02.2013 Treatment of low-grade non-hodgkin lymphoma Lymphomas are described as low grade if the cells appear to be dividing slowly. There are several kinds of low-grade

More information

OVERVIEW OF LECTURE CONTENT: INTRODUCTION AND DEFINITIONS OVERVIEW OF THE LYMPHOCYTE + HISTIOCYTE SUBSETS AND THEIR FUNCTIONS OVERVIEW OF NORMAL LYMPH

OVERVIEW OF LECTURE CONTENT: INTRODUCTION AND DEFINITIONS OVERVIEW OF THE LYMPHOCYTE + HISTIOCYTE SUBSETS AND THEIR FUNCTIONS OVERVIEW OF NORMAL LYMPH AN INTRODUCTION TO THE LYMPHOPROLIFERATIVE DISORDERS BY DR Y PERNER DEPARTMENT OF ANATOMICAL PATHOLOGY OVERVIEW OF LECTURE CONTENT: INTRODUCTION AND DEFINITIONS OVERVIEW OF THE LYMPHOCYTE + HISTIOCYTE

More information

Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Breast Cancer

Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Breast Cancer Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Breast Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_breast_cancer

More information

Leukemias and Lymphomas: A primer

Leukemias and Lymphomas: A primer Leukemias and Lymphomas: A primer Normal blood contains circulating white blood cells, red blood cells and platelets 700 red cells (oxygen) 1 white cell Neutrophils (60%) bacterial infection Lymphocytes

More information

Disclosures. I have no disclosures.

Disclosures. I have no disclosures. Not Your Own Marrow Jenni Krajewski, MD Clinical Assistant Professor, Rutgers New Jersey Medical School Attending Physician, Pediatric Blood and Marrow Transplantation The Institute for Pediatric Cancer

More information

An overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham

An overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham An overview of CLL care and treatment Dr Dean Smith Haematology Consultant City Hospital Nottingham What is CLL? CLL (Chronic Lymphocytic Leukaemia) is a type of cancer in which the bone marrow makes too

More information

Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease

Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease Bone Marrow (Stem Cell) Transplant for Sickle Cell Disease 1 Produced by St. Jude Children s Research Hospital Departments of Hematology, Patient

More information

A Science Writer s Guide to Multiple Myeloma

A Science Writer s Guide to Multiple Myeloma A Science Writer s Guide to Multiple Myeloma 1 A Science Writer s Guide to Multiple Myeloma A Science Writer s Guide to Multiple Myeloma PREFACE Blood cancers and related disorders a serious health risk

More information

Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma

Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine with rituximab for the first-line treatment of advanced indolent non-hodgkin's and mantle cell lymphoma Bendamustine with rituximab for the first-line

More information

A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on

A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on examination. She also has fever, weight loss, and sweats. What

More information

Haematopoietic stem cell transplantation in Hong Kong

Haematopoietic stem cell transplantation in Hong Kong S C I E N T I F I C P A P E R Haematopoietic stem cell transplantation in Hong Kong Albert KW Lie WY Au Raymond Liang 李 國 維 區 永 仁 梁 憲 孫 The first case of haematopoietic stem cell transplant (HSCT) was

More information

Cancer. 9p21.3 deletion. t(12;21) t(15;17)

Cancer. 9p21.3 deletion. t(12;21) t(15;17) CANCER FISH PROBES INDIVIDUAL AND PANEL S Acute Lymphoblastic Leukemia (ALL) ALL FISH Panel (includes all probes below) 8010 LSI MYB/CEP6 LSI p16 (CDKN2A) LSI BCR/ABL with ASS LSI ETV6 (TEL)/AML1 (RUNX1)

More information

PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA

PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA UNFAVORABLE Advanced age High leukocyte count at diagnosis Presence of myeloid antigens Late achievement of CR Chromosomal abnormalities: t(9:22)(q34:q11) t(4;11)(q21;q23)

More information

MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)

MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010) MALIGNANT LYMPHOMAS Dr. Olga Vujovic (Updated August 2010) Malignant lymphomas consist of Hodgkin and non-hodgkin lymphomas. The current management of these diseases involves a multi-disciplinary approach.

More information

Stem Cell Transplantation in Adults

Stem Cell Transplantation in Adults Recommendation Report Stem Cell Transplantation in Adults K. Imrie, R.B. Rumble, M. Crump, the Advisory Panel on Bone Marrow and Stem Cell Transplantation, and the Hematology Disease Site Group of Cancer

More information

Infosheet. Allogeneic stem cell transplantation in myeloma. What is the principle behind stem cell transplantation?

Infosheet. Allogeneic stem cell transplantation in myeloma. What is the principle behind stem cell transplantation? Infosheet Allogeneic stem cell transplantation in myeloma High-dose therapy and autologous stem cell transplantation is currently the first-line treatment standard of care for younger/fitter myeloma patients.

More information

Bone Marrow/Stem Cell Transplant

Bone Marrow/Stem Cell Transplant Blue Distinction Centers for Transplants Program Selection Criteria for 2010 Mid-Point Designations To qualify as a Blue Distinction Center for Transplants (), each facility must satisfy s quality based

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description

More information

Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis

Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis T Kozák, P Lhotáková Department of Clinical Haematology, 3r d School of Medicine,

More information

Blood and Marrow Stem Cell Transplantation

Blood and Marrow Stem Cell Transplantation Blood and Marrow Stem Cell Transplantation Revised 2013 A Message from Louis J. DeGennaro, PhD President and CEO of The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society (LLS) is committed to

More information

What is chronic lymphocytic leukaemia?

What is chronic lymphocytic leukaemia? Revised October 2011 What is chronic lymphocytic leukaemia? The diagnosis of a blood cancer can be a devastating event for patients, families and friends. It is therefore vital for everyone to have access

More information

STEM CELL TRANSPLANTS

STEM CELL TRANSPLANTS UAMS Information on STEM CELL TRANSPLANTS What is a Stem Cell Transplant? A stem cell transplant is an infusion of stem cells following high-dose chemotherapy. The infused cells effectively rescue the

More information

Pros and Cons of Stem Cell Sources and their availability in Africa. Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa

Pros and Cons of Stem Cell Sources and their availability in Africa. Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa Pros and Cons of Stem Cell Sources and their availability in Africa Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa Introduction The ability to perform a haematopoietic stem

More information

Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood

Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood [Track 2: What Is a Transplant?] Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood can be an effective treatment for people with blood cancers such as leukemia,

More information

Non-Hodgkin s lymphomas (NHLs) are a

Non-Hodgkin s lymphomas (NHLs) are a Oncology 33 Non-Hodgkin s lymphoma in the elderly The incidence of non-hodgkin s lymphoma (NHL) is increasing, and this increase is even more rapid in the older population. Although treatment of NHL in

More information

Reference: NHS England B04/P/a

Reference: NHS England B04/P/a Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation (HSCT) (All Ages): Revised Reference: NHS England B04/P/a 1 NHS England Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Velcade Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antineoplastic Client: PS Inj Approval Date: 10/2/2004 Revision Date: 5/22/2007

More information

Chronic Lymphocytic Leukemia. Case Study. AAIM Triennial October 2012 Susan Sokoloski, M.D.

Chronic Lymphocytic Leukemia. Case Study. AAIM Triennial October 2012 Susan Sokoloski, M.D. Chronic Lymphocytic Leukemia AAIM Triennial October 2012 Susan Sokoloski, M.D. Case Study 57 year old male, trial application for $1,000,000 Universal Life coverage Cover letter from sales agent indicates

More information

A Clinical Primer. for Managed Care Stakeholders

A Clinical Primer. for Managed Care Stakeholders reviews therapy Diagnosing, Staging, and Treating Multiple Myeloma: A Clinical Primer for Managed Care Stakeholders by Ralph V. Boccia, MD, FACP, Medical Director, Center for Cancer and Blood Disorders

More information

Cytoreductive Therapy for Autologous Cell Therapy in HIV

Cytoreductive Therapy for Autologous Cell Therapy in HIV Cytoreductive Therapy for Autologous Cell Therapy in HIV Ronald Mitsuyasu, MD Professor of Medicine UCLA Center for Clinical AIDS Research and Education (CARE Center) HSC Transfer from CCR5-delta 32 Donor

More information

Non Hodgkin Lymphoma:

Non Hodgkin Lymphoma: Non Hodgkin Lymphoma: Non Hodgkin Lymphoma, often referred to as NHL, is a cancer originating in the lymphocytes, a type of blood cell, which are integral to the body s immune system. Non Hodgkin Lymphoma

More information

The Immunobiology Working Party

The Immunobiology Working Party The Immunobiology Working Party Educational Event 28-29 September 2013,, Italy Faculty of Medicine, University of Chairman: Andrea Velardi I am happy to announce the upcoming EBMT Immunobiology Working

More information

Genomics in Hematology

Genomics in Hematology Università degli Studi di Perugia Genomics in Hematology January 29-31, 2012 Perugia Camera di Commercio Congress Center January 29 th, 2012 Opening Session Teatro del Pavone Chairs: Franco Aversa, Cristina

More information

Blood cells are vital to the human body

Blood cells are vital to the human body Candide FONT-SALA Blood cells are vital to the human body Red cells transport oxygen From http://www.english-online.at/biology/blood/blood-supply-and-blood-diseases.htm Red cell life span 120 days 200

More information

Cord Blood Stem Cell Transplantation

Cord Blood Stem Cell Transplantation LEUKEMIA LYMPHOMA MYELOMA FACTS Cord Blood Stem Cell Transplantation No. 2 in a series providing the latest information on blood cancers Highlights Umbilical cord blood, like bone marrow and peripheral

More information

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart

More information

The Treatment of Leukemia

The Treatment of Leukemia The Treatment of Leukemia Guest Expert: Peter, MD Associate Professor of Hematology Director, Yale Cancer Center Leukemia Program www.wnpr.org www.yalecancercenter.org Hi, I am Bruce Barber and welcome

More information

Acute myeloid leukemia (AML)

Acute myeloid leukemia (AML) Acute myeloid leukemia (AML) Adult acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. Adult

More information

EUROCORD. in 49 countries and 484 transplant centres* 264 EBMT 4847 (73%) cases 220 Non-EBMT 1797 (27%) cases

EUROCORD. in 49 countries and 484 transplant centres* 264 EBMT 4847 (73%) cases 220 Non-EBMT 1797 (27%) cases ! 21%! EUROCORD 6756 cord blood transplantations performed from 1988 to March 2010 in 49 countries and 484 transplant centres* 264 EBMT 4847 (73%) cases 220 Non-EBMT 1797 (27%) cases * missing center

More information

Allogeneic stem cell transplant in HIV-1-infected individuals

Allogeneic stem cell transplant in HIV-1-infected individuals Allogeneic stem cell transplant in HIV-1-infected individuals Javier Martinez-Picado UNIVERSITAT DE VIC Barriers to cure HIV infection Residual Replication Immune activation Inflammation Latent Infection

More information

Ar Mino changes including adjustment of therapy algorithms

Ar Mino changes including adjustment of therapy algorithms cute Myeloid Leukemia Updated April 2008 by Dr. Richard Wells* Updates: Ar Mino changes including adjustment of therapy algorithms Introduction Acute myeloid leukemia is a relatively uncommon cancer with

More information

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly

More information